Bone Medical (BNE)

Shares / Stock Code


Stock Exchange / Sharemarket


Bone Medical (BNE), along with its subsidiaries, is engaged in the development of therapeutics to prevent and/or treat bone and joint diseases and conditions, especially osteoporosis, osteoarthritis and arthritis. The Company operates in the biopharmaceutical segment in Australia. The Company’s wholly owned subsidiaries include Bone Limited and Owein Pty Ltd. Bone Limited has license agreements for the technologies of Axcess, Mozaic, Vaxcine, and Lexicon from the licensors Axcess Limited, Mozaic Discovery Limited, Vaxcine Limited and Lexicon Limited. During the fiscal year ended June 30, 2009, the Company had three clinical projects and one pre-clinical project.

Bone Medical Limited (Bone has licensed proprietary oral delivery technology for use in developing treatments for bone and joint diseases. If BNE is able to successfully develop oral forms of drugs that must currently be administered by injection or inhalation, then this would be a key differentiating factor for the company. As BNE has no products on market, it has no customers currently. There are many treatments available for osteoporosis. Novartis and Nobex are each developing oral calcitonins, and Eli Lilly and GlaxoSmithKline are each developing oral parathyroid hormones. There are no oral Tumour Necrosis Factor (TNF) treatments as yet, but Amgen, Abbott and Centocor (J&J) each have blockbuster injectible anti-TNF drugs. An effective oral drug in this class would be a huge seller.

Bone Medical History

The company changed name from Revenir Limited (REV) to Bone Medical Limited (BNE) in August 2004. In September 2005, Proxima Concepts transferred to BNE the remaining 20% of UK-based Bone Ltd, which BNE did not already own. Bone is the licensee of the Proxima Concepts technology that underlies BNE's R&D pipeline. It was formed with the purpose of focusing on breakthrough treatments for bone and joint diseases and degeneration, in particular osteoporosis and arthritis. Its strategic goal is to be a leading international development-based company in musculo-skeletal therapies by 2012.

Bone Medical (BNE) Products and Services

  • Development and commercialisation of treatments for bone disease

Bone Medical (BNE) Locations and Subsidiaries

Bone Medical Head Office
PO Box 1110,
WA 6983

Phone: (08) 9355 5123
Fax: (08) 9355 5210

Bone Medical (BNE) Share Price

Submitted by ASX Listed Company on 3 March, 2010 - 21:35